These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 10534061)

  • 1. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.
    Lee JL; Gooley T; Bensinger W; Schiffman K; McDonald GB
    Biol Blood Marrow Transplant; 1999; 5(5):306-15. PubMed ID: 10534061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.
    Abate ME; Paioli A; Cammelli S; Cesari M; Longhi A; Palmerini E; Ferrari S; Carretta E; Picci P; Piscaglia F
    Bone Marrow Transplant; 2018 May; 53(5):591-599. PubMed ID: 29335623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
    Przepiorka D; Khouri I; Thall P; Mehra R; Lee MS; Ippoliti C; Giralt S; Gajewski J; van Besien K; Andersson B; Körbling M; Deisseroth AB; Champlin R
    Bone Marrow Transplant; 1999 May; 23(10):977-81. PubMed ID: 10373061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study.
    McDonald GB; Evans AT; McCune JS; Schoch G; Ostrow JD; Gooley TA
    Lancet Haematol; 2016 Nov; 3(11):e516-e525. PubMed ID: 27968820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
    Styler MJ; Crilley P; Biggs J; Moul J; Copelan E; Topolsky D; Avalos B; Penza S; Sabol P; Downs K; Szer J; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Jul; 18(1):171-6. PubMed ID: 8832011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma.
    Lee SC; Kim SJ; Lee DH; Kim WS; Suh C; Won JH
    Bone Marrow Transplant; 2010 Apr; 45(4):801-2. PubMed ID: 19767780
    [No Abstract]   [Full Text] [Related]  

  • 8. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
    Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
    Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.
    Schechter T; Perez-Albuerne E; Lin TF; Irwin MS; Essa M; Desai AV; Frangoul H; Yanik G; Dupuis LL; Jacobsohn D; Kletzel M; Ranalli M; Soni S; Seif AE; Grupp S; Dvorak CC
    Bone Marrow Transplant; 2020 Mar; 55(3):531-537. PubMed ID: 30181580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
    Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
    Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.
    Cacchione A; LeMaitre A; Couanet DV; Benhamou E; Amoroso L; Simonnard N; Hartmann O
    Bone Marrow Transplant; 2008 Oct; 42(7):449-54. PubMed ID: 18587430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.
    McDonald GB; Hinds MS; Fisher LD; Schoch HG; Wolford JL; Banaji M; Hardin BJ; Shulman HM; Clift RA
    Ann Intern Med; 1993 Feb; 118(4):255-67. PubMed ID: 8420443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
    Hawkins D; Barnett T; Bensinger W; Gooley T; Sanders J
    Med Pediatr Oncol; 2000 May; 34(5):328-37. PubMed ID: 10797354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
    O'Donnell PH; Artz AS; Undevia SD; Pai RK; Del Cerro P; Horowitz S; Godley LA; Hart J; Innocenti F; Larson RA; Odenike OM; Stock W; Van Besien K
    Leuk Lymphoma; 2010 Dec; 51(12):2240-9. PubMed ID: 20919852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors.
    Bouligand J; Le Maitre A; Valteau-Couanet D; Grill J; Drouard-Troalen L; Paci A; Hartmann O; Benhamou E; Vassal G
    Clin Pharmacol Ther; 2007 Oct; 82(4):402-9. PubMed ID: 17392724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.
    Kusumi E; Kami M; Kanda Y; Murashige N; Seki K; Fujiwara M; Koyama R; Komatsu T; Hori A; Tanaka Y; Yuji K; Matsumura T; Masuoka K; Wake A; Miyakoshi S; Taniguchi S
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1302-9. PubMed ID: 17162212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
    Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
    Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation.
    Wada F; Nishikori M; Hishizawa M; Watanabe M; Aiba A; Kitano T; Shimazu Y; Shindo T; Kondo T; Takaori-Kondo A
    Int J Hematol; 2020 Nov; 112(5):609-613. PubMed ID: 32980953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.
    Ozkaynak MF; Weinberg K; Kohn D; Sender L; Parkman R; Lenarsky C
    Bone Marrow Transplant; 1991 Jun; 7(6):467-74. PubMed ID: 1908340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.